SAB Biotherapeutics, Inc. (SABS) Form 8-K — May 4, 2026

$SABSForm 8-KItems 1.01, 9.01Filed May 4, 2026, 4:35 PM ET0001193125-26-204125Original filing

SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for the clinical and commercial manufacturing of its product candidate, SAB-142. The agreement has a five-year term commencing upon FDA approval, featuring a minimum aggregate spend commitment of $36 million that scales annually from $1.5 million in the first year to $15.0 million in the fifth.

Key figures

Deal Value Usd: 36000000
Term Years: 5
Minimum Spend Year1: $1.5 million
Minimum Spend Year2: $3.0 million
Minimum Spend Year3: $6.0 million
Minimum Spend Year4: $10.5 million
Minimum Spend Year5: $15.0 million

Price after filing

1 day: -0.3%7 days: +0.8%30 days: -8.9%

Close on the filing date to close N calendar days later (from $3.69). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.